HMPL004-6599

N/A

Report date: 2024/11/27 10:27:03
NME

Base Information

Drug NameHMPL004-6599
Drug Alias NameHMPL004-6599
ClassificationSmall moleculesNatural product/Extract
Mechanisms of ActionIL-6 receptor antagonistsInterleukin-1 beta modulatorsNuclear factor NF-kappa-B complex inhibitors +[4] 
TargetsIL-6 receptorInterleukin-1 betaNuclear factor NF-kappa-B complex +[4] 
Therapy Area/IndicationsCrohn DiseaseColitis, Ulcerative
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustralia
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNestle Health Science
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNutrition Science Partners Ltd
Active IndicationsN/A
Inactive IndicationsCrohn DiseaseColitis, Ulcerative

Other Information

ATC CodeN/A
Related LinksN/A